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INTRODUCTION 
Angiotensin-converting enzyme inhibitors (ACEIs) are widely 
used to treat patients with hypertension and refractory cardiac 
failure. It has been estimated that more than 40 million people 
worldwide are currently receiving ACEIs, and their use is ex-
pected to continue increasing.
Cutaneous adverse effects caused by these drugs include urti-
caria, maculopapular and lichenoid eruptions, pityriasis rosea-
like rash, pemphigus, photosensitivity, and linear IgA dermato-
sis. The most common adverse effects observed in patients trea-
ted with ACEIs are a dry nonproductive cough occurring in 15–
30% of patients and angioedema.
Angioedema was first described by Milton in 1876
1 and was 
termed angioneurotic angioedema by Quincke in 1882.
2 Drug-
induced angioedema has been associated with the use of vari-
ous medications, including nonsteroidal anti-inflammatory 
drugs (NSAIDs), ACEIs, radiocontrast media, angiotensin II re-
ceptor antagonists, antibiotics, proton pump inhibitors, statins, 
fibrinolytic agents, estrogens, diuretics, calcium channel block-
ers, beta blockers, and psychotropic drugs (serotonin reuptake 
inhibitors). The drugs most frequently involved are NSAIDs and 
ACEIs.
3,4
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Angioedema induced by ACEIs is present in 0.1–0.7% of treat-
ed patients
5 and more often involves the head, neck, face, lips, 
tongue and larynx. In rare cases, it can involve visceral organs 
such as the gut. Life-threatening edema of the upper airway, 
which is present in 25–39% of cases of ACEI angioedema,
6,7 can 
be resistant to treatment and even fatal.
8,9
The mechanism of angioedema in patients taking ACEIs in-
volves the inhibition of ACE, which blocks the conversion of 
angiotensin, reduces the catabolism of bradykinin, and increas-
es its activity.
10 Decreased aminopeptidase P (APP) activity and 
dipeptidyl peptidase P in the substance P degradation path-
ways also seem to play a role.
11 Furthermore, a polymorphism 
of XPNPEP2 (the -2399 A variant), a candidate gene encoding 
membrane-bound APP, is associated with reduced APP activity 
and a higher incidence of ACEI-induced angioedema.
12
Angioedema associated with ACEIs is most commonly ob-
served at the beginning of treatment, but it may also develop 
Original Article
Allergy Asthma Immunol Res. 2010 July;2(3):195-198.
doi: 10.4168/aair.2010.2.3.195
pISSN 2092-7355 • eISSN 2092-7363
Purpose:  To investigate the incidence and clinical characteristics of angioedema associated with the use of angiotensin-converting enzyme inhibi-
tors (ACEIs) in an outpatient allergy department. Methods:  A retrospective review of medical records of new patients seen in an allergy clinic. De-
mographic and clinical data of patients with ACEI-induced angioedema were analyzed. Results:  Nine (0.37%) out of 2,421 new patients attending 
the allergy clinic developed ACEI-associated angioedema. Enalapril was the drug most frequently incriminated. The onset of the angioedema was 
as early as after the first dose or as late as 2 years after beginning treatment. Six patients experienced life-threatening angioedema involving the 
tongue, oropharynx, or larynx, and two patients required transfer to the intensive care unit. One patient required a tracheostomy. Conclusions:  An-
giotensin-converting enzyme inhibitor treatment is often responsible for angioedema, especially involving the upper airways. Due to the high propor-
tion of the population exposed to ACEIs and to the severity of this adverse effect, it is important that physicians consider ACEIs as possible inducers 
when evaluating patients with acute or recurrent angioedema.
Key Words:  Angiotensin-converting enzyme inhibitors; angioedema; bradykinin; captopril; enalapril
This is an Open Access article distributed under the terms of the Creative Commons Attribution Non-Commercial License (http://creativecommons.org/licenses/by-nc/3.0/) which permits 
unrestricted non-commercial use, distribution, and reproduction in any medium, provided the original work is properly cited.
Correspondence to:  Mario Sa@nchez-Borges, MD, P.O.B.A. International, 
#635, Miami, Florida 33102-5255, USA.
Tel/Fax: +58-212-2615284; E-mail: sanchezbmario@gmail.com
Received: February 2, 2010; Accepted: March 26, 2010
•There are no financial or other issues that might lead to conflict of interest.Sa@nchez-Borges et al.
Allergy Asthma Immunol Res. 2010 July;2(3):195-198.  doi: 10.4168/aair.2010.2.3.195
Volume 2, Number 3, July 2010
196 http://e-aair.org
long after the drug has been started.
13-15 Sometimes, angioede-
ma is present in patients taking ACEIs and other concomitant 
drugs such as NSAIDs.
16,17 This paper presents clinical data 
from a group of patients with ACEI-induced angioedema at-
tending an allergy clinic between January 2005 and December 
2009.
MATERIALS AND METHODS
This is a retrospective review of the medical records of pa-
tients attending an allergy clinic in Caracas, Venezuela, for 5 
years, from January 2005 to December 2009, with the aim of de-
termining the incidence of angioedema associated with the use 
of ACEIs. Records of all new patients seen at the Allergy and 
Clinical Immunology Department of Cli@nica El Avila during 
this period were reviewed, and only those with a definitive diag-
nosis of ACEI-induced angioedema were included in the study. 
Clinical data retrieved from the history included age, gender, 
race, history of other medical or allergic conditions, anatomical 
distribution of angioedema, severity, concomitant therapy, 
time of onset, responsible ACEI, and management. For ethical 
considerations, no challenge or re-exposure tests with ACEIs 
were carried out, as the angioedema in these patients may be 
life threatening. The diagnosis was based on the clinical picture, 
temporal relationship to drug exposure, absence of other possi-
ble causes of angioedema, and disappearance of the clinical 
manifestations after discontinuing the drug.
RESULTS
During the study period, 2,421 new patients were seen in the 
outpatient clinic of the Allergy and Immunology Department. 
Nine patients (0.37%) developed angioedema related to ACEI 
treatment. The demographic and clinical data of those patients 
are presented in Table 1.
Seven patients were males, and two were female; their mean 
age was 63.4±10.3 years (range 51–77 years). Seven patients 
were American Caucasoid, one was Caucasian, and one was 
black. The angioedema was localized to the tongue in 5 patients, 
lips in 4, diffusely on the face in 2, larynx in 2, and eyelids in 1 
(Figure). The time of onset of the angioedema in relation to 
ACEI therapy was obtained for five patients and ranged from 30 
minutes after the first drug exposure to 2 years.
Enalapril was responsible for the angioedema in 5 patients, 
captopril in 3, and perindopril in 1. Seven patients were treated 
in the emergency department and two in the intensive care 
unit. According to the severity and degree of compromise of 
airway patency, six patients experienced life-threatening an-
gioedema involving the tongue, oropharynx or larynx. Treat-
ment consisted of parenteral and oral corticosteroids and anti-
Table 1. Demographic and clinical data in patients with ACEI-induced angioedema
Age/
Gender
Race Past history Localization
Time of
onset
Drug
Where
treated
Concomitant 
medications
Life
threat?
Management
55/F AC Chronic Face 30 min (1
st dose)  Captopril ER Verapamil
Rosiglitazone
Aspirin
No Betamethasone
Urticaria Eyelids Chlorpheniramine
Lips
66/M AC Gout Tongue 2 years Enalapril ER Atenolol
Lercanidipine
Allopurinol
Colchicine
Atorvastatin
Yes Prednisone
Fexofenadine
71/F C None Tongue U Perindopril ER Atenolol No U
51/M AC Allergic rhinitis
Penicillin allergy
Lips U Enalapril ER None No Betamethasone
Cetirizine
77/M AC None Larynx U Enalapril ER None Yes Dexametasone
Loratadine
77/M AC Ischemic heart disease Tongue 1 year Captopril ER Glafornil
Glimepiride
Aspirin
Gemfibrozil
Yes Prednisone
Diabetes Chlorpheniramine
56/M AC Sleep apnea Tongue U Captopril ICU Aspirin
Vitamin C
Diclofenac
Yes Betamethasone
Larynx
66/M AC Allergic rhinitis Tongue 1 year Enalapril ICU Sildenafil
Nadolol
Nifedipine
Yes Dexametasone
Polycystic kidney Lips Tracheostomy
52/M B Alcoholism Face
Lips
6 months Enalapril ER Amlodipine
Aspirin
Yes Hydrocortisone
Chlorpheniramine
AC, American Caucasoid; C, Caucasian; B, Black; U, unknown; ER, Emergency room; ICU, Intensive care unit.ACEIs and angioedema
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Figure. (A) A male, 51 years old black patient who experienced diffuse facial and lip angioedema during treatment with enalapril. (B) The same patient as in (A). No-
tice angioedema resolution after 6 days of enalapril discontinuation.
A
B
histamines in all patients, and a tracheostomy was performed 
in one patient. In none of the patients was the diagnosis of 
ACEI-associated angioedema made by the medical services in-
volved in managing the acute episode.
DISCUSSION
Various risk factors for ACEI-induced angioedema have been 
identified, including black race, female gender, previous drug 
rash,
14 smoking habit,
18 age older than 65 years, seasonal aller-
gies, recent initiation of ACEIs (first week of therapy), obesity, 
upper airway surgery or trauma, sleep apnea and immunosup-
pression in cardiac and renal transplant recipients.
19
The issue of adverse effects of ACEIs is clinically relevant due 
to the large number of subjects exposed to these drugs, which 
is increasing. Various ACEIs, including enalapril, lisinopril, cap-
topril, ramipril, imidapril, benazepril, trandolapril and perin-
dopril, are in use in many countries. Since angioedema is a 
drug class effect, it is very important that physicians consider 
these drugs in the differential diagnosis of angioedema and 
give proper advice on avoiding all ACEIs to these patients.
All nine patients seen in our allergy clinic had severe angioe-
dema, which was considered life threatening in approximately 
two-thirds of the cases. ACEIs were rarely considered as possi-
ble etiologic factors by the treating physicians in the emergency 
room or hospital ward. Only symptomatic treatment with corti-
costeroids and antihistamines was given before referral to the 
allergy specialist. Many of the patients had repeated episodes of 
angioedema before being referred for further evaluation.
Regarding the management of patients with ACEI angioede-
ma, the most important recommendation is to avoid ACEIs and 
modify the treatment, generally with the agreement of the treat-
ing physician. Antihypertensive medications from other phar-
macologic groups are indicated. In our patients, calcium chan-
nel blockers were often recommended. According to Malde et 
al.,
20 only 8% of patients who experienced angioedema from 
ACEIs previously develop angioedema with angiotensin recep-
tor blockers (ARB). During the 5-year period of our investiga-Sa@nchez-Borges et al.
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tion, one patient, a 64-year-old male, developed eyelid and lip 
angioedema after 2 years of treatment with losartan, an ARB; 
this resolved after the drug was stopped and therapy was 
switched to amlodipine.
Recently, Weber et al.,
21 proposed a new treatment for ACEI-
associated angioedema. They postulated that since bradykinin 
is a major mediator of angioedema from ACEIs, the bradykinin 
inhibitor icatibant, presently used in patients with hereditary 
angioedema, could be effective for these patients.
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